Brainsway Ltd (BWAY)vsNovartis AG ADR (NVS)
BWAY
Brainsway Ltd
$13.57
-0.29%
HEALTHCARE · Cap: $560.10M
NVS
Novartis AG ADR
$140.37
+0.43%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 93306% more annual revenue ($56.69B vs $60.70M). NVS leads profitability with a 22.5% profit margin vs 15.6%. NVS trades at a lower P/E of 20.7x. NVS earns a higher WallStSmart Score of 51/100 (C-).
BWAY
Buy50
out of 100
Grade: C-
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BWAY.
Margin of Safety
-50.3%
Fair Value
$93.40
Current Price
$140.37
$46.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.4% year-over-year
Earnings expanding 64.6% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : BWAY
The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 14.0%. Revenue growth of 35.4% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : BWAY
The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 60.6x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
BWAY profiles as a growth stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
BWAY is growing revenue faster at 35.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 50/100), backed by strong 22.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?